By Billy Candra 
Findings from a multi-institutional, international study led by researchers from the Mayo Clinic Comprehensive Cancer Center have significantly advanced the understanding of genetic alterations in the BRCA2 gene, a key player in hereditary cancer risk. The researchers completed a comprehensive functional assessment of all possible variants within the crucial DNA-binding domain of BRCA2, resulting in the clinical classification of an unprecedented 91% of variants of uncertain significance (VUS) in this part of the gene. This groundbreaking achievement dramatically improves the accuracy of genetic testing for hereditary cancers and will allow healthcare professionals to offer more precise risk assessments and personalized treatment plans for individuals carrying these previously ambiguous variants. Published in the esteemed journal Nature, this research marks a pivotal moment in the ongoing quest to refine precision medicine strategies for cancer prevention and treatment.
Understanding the Crucial Role of BRCA Genes in Cancer Predisposition
The BRCA1 and BRCA2 genes are among the most well-known and extensively studied human genes associated with hereditary cancer risk. Discovered in the mid-1990s, these genes are fundamental tumor suppressors, meaning they play a critical role in preventing the uncontrolled growth of cells. Their primary function lies in DNA repair, specifically through a pathway called homologous recombination, which is essential for fixing double-strand breaks in DNA. When BRCA1 or BRCA2 genes are functioning correctly, they act as guardians of the genome, ensuring its stability and preventing the accumulation of mutations that can lead to cancer.
However, when an individual inherits a deleterious mutation (a pathogenic variant) in one of these genes, their ability to repair damaged DNA is compromised. This genetic predisposition significantly increases their lifetime risk of developing certain cancers, most notably breast and ovarian cancer, but also prostate cancer, pancreatic cancer, and melanoma. For women with a pathogenic BRCA1 or BRCA2 mutation, the lifetime risk of breast cancer can be as high as 45-85%, compared to approximately 12% in the general population. The risk of ovarian cancer can also be substantially elevated, ranging from 11-40% depending on the specific gene and family history. Men carrying these mutations face an increased risk of breast cancer (up to 5-10% lifetime risk for BRCA2 carriers) and a higher likelihood of aggressive prostate cancer.
Genetic testing for BRCA1 and BRCA2 mutations has become a standard practice for individuals with a strong family history of these cancers or those diagnosed with specific cancer types at an early age. The information derived from such tests can guide crucial decisions regarding cancer screening protocols (e.g., earlier and more frequent mammograms and MRI scans), prophylactic surgeries (such as preventive mastectomies or oophorectomies), and targeted treatment options if cancer develops.
The Enduring Challenge of Variants of Uncertain Significance (VUS)
Despite the immense benefits of BRCA1/2 genetic testing, a significant hurdle has persisted in its clinical application: the identification of Variants of Uncertain Significance, or VUS. A VUS is a genetic alteration that has been identified in a gene, but its clinical impact – whether it is benign (harmless) or pathogenic (disease-causing) – cannot be definitively determined based on current scientific knowledge. Unlike clear pathogenic mutations or benign polymorphisms, VUS fall into a frustrating "gray area" that creates considerable ambiguity for both patients and healthcare providers.
The prevalence of VUS in BRCA1 and BRCA2 testing has historically been a major challenge. While the exact proportion varies depending on the population tested and the genetic sequencing technology used, it’s not uncommon for 10-20% or more of individuals undergoing BRCA testing to receive a VUS result. For patients, a VUS can be a source of profound anxiety and uncertainty. They are left in limbo, unsure whether they carry an increased cancer risk, and thus unable to make informed decisions about preventive measures, screening intensity, or even family planning. This ambiguity can lead to psychological distress, unnecessary medical procedures based on incomplete information, or, conversely, a false sense of security that could delay necessary interventions.
For clinicians, VUS results complicate risk assessment and management. Without a clear classification, it is difficult to recommend appropriate screening intervals, advise on prophylactic surgeries, or determine eligibility for targeted therapies that are highly effective against BRCA-mutated cancers. This diagnostic dilemma has highlighted a critical unmet need in precision oncology – the ability to precisely interpret every genetic alteration found in clinically relevant genes. Previous methods for VUS classification, often relying on computational predictions, population frequency data, or limited functional assays, have been insufficient to resolve the vast majority of these ambiguous variants.
A Technological Leap: CRISPR-Cas9 Unlocks BRCA2’s Secrets
The study, spearheaded by researchers at the Mayo Clinic Comprehensive Cancer Center and published in Nature, represents a monumental leap forward in addressing the VUS conundrum in BRCA2. At the heart of this achievement lies the innovative application of CRISPR-Cas9 gene-editing technology. This revolutionary tool, often dubbed "molecular scissors," allows scientists to make precise edits to DNA, enabling them to alter specific genes with unprecedented accuracy and efficiency.
In this context, the research team utilized CRISPR-Cas9 to systematically introduce and analyze the functional impact of an astounding nearly 7,000 BRCA2 variants. Instead of waiting for these variants to appear in patient samples, the researchers proactively created a comprehensive library of all possible single-amino acid substitutions within the crucial DNA-binding domain of the BRCA2 gene. This domain is particularly vital because it dictates how the BRCA2 protein interacts with DNA to facilitate repair, making alterations in this region highly likely to impact gene function and, consequently, cancer risk.
The methodology involved a high-throughput functional assessment where each engineered BRCA2 variant was tested for its ability to perform its essential DNA repair function. Cells carrying functional BRCA2 variants would exhibit normal growth and survival, while those with pathogenic variants would show impaired DNA repair, leading to increased sensitivity to DNA-damaging agents or reduced viability. By meticulously observing these cellular phenotypes for thousands of variants in parallel, the researchers could definitively distinguish between those that increased cancer risk (pathogenic/likely pathogenic) and those that did not (benign/likely benign). This systematic, data-driven approach moved beyond theoretical predictions, providing empirical evidence for the functional consequence of each variant.
Unprecedented Classification: A Catalog for Clinical Care
The culmination of this exhaustive functional assessment was the clinical classification of an astonishing 91% of VUS found within the DNA-binding domain of BRCA2. This figure represents a dramatic improvement over previous classification rates and effectively transforms a vast gray area into a realm of clarity. The newly classified variants are now categorized into clinically actionable groups, providing clear guidance for patient management.
"This research is a major advancement in understanding the role of many BRCA2 variants in cancer predisposition," states Dr. Fergus Couch, the Zbigniew and Anna M. Scheller Professor of Medical Research at Mayo Clinic and a lead author of the study. His statement underscores the profound impact of this work on patient care. "Until now, patients who carried VUS often worried if they would develop cancer, but now with the classification of these variants, we can provide a clearer picture of cancer risk and tailor both prevention strategies as well as breast cancer treatment accordingly."
The study effectively creates a comprehensive "catalog" of every possible VUS in this critical region of BRCA2. This catalog is not merely an academic exercise; it is a practical tool designed to guide clinical care, offering definitive answers where only uncertainty existed before. The detailed functional data underpinning these classifications provides a robust evidence base for reinterpreting countless genetic test results and improving the accuracy of future diagnoses.
Immediate and Far-Reaching Clinical Implications
The implications of these findings are immediate and profound, poised to reshape several facets of hereditary cancer management:
1. Revolutionizing Genetic Testing and Counseling:
Genetic testing laboratories worldwide, particularly those involved with the ClinVar BRCA1/2 expert panel, are already integrating this new information. Patients who previously received a VUS result in this BRCA2 domain may be notified about the reclassification of their variant. This reclassification can transform a nebulous result into a clear directive, alleviating anxiety and enabling patients to make informed decisions about their health. Genetic counselors will now have definitive data to provide more precise risk assessments, tailoring recommendations for screening, lifestyle modifications, and prophylactic surgeries with greater confidence.
2. Guiding Personalized Cancer Prevention:
For individuals reclassified as carrying a pathogenic or likely pathogenic BRCA2 variant, clear guidelines for intensified cancer screening can be implemented. This includes earlier and more frequent mammograms, breast MRIs, and ovarian cancer screening. Prophylactic surgeries, such as risk-reducing mastectomies or salpingo-oophorectomies, can be discussed with greater certainty, allowing patients to weigh the benefits against the risks with a clearer understanding of their genetic predisposition. Conversely, individuals whose VUS is reclassified as benign or likely benign can be reassured, potentially avoiding unnecessary anxiety, invasive procedures, and intensive surveillance.
3. Optimizing Cancer Treatment Strategies:
One of the most significant clinical impacts lies in the realm of cancer treatment. Patients diagnosed with breast, ovarian, pancreatic, or prostate cancer who carry pathogenic BRCA2 variants are known to respond exceptionally well to a class of targeted drugs called PARP inhibitors. Poly (ADP-ribose) polymerase (PARP) inhibitors work by exploiting a weakness in cancer cells with BRCA mutations. Since these cells already have impaired DNA repair through homologous recombination, inhibiting PARP (another DNA repair pathway) creates a synthetic lethality, causing the cancer cells to accumulate too much DNA damage and die, while healthy cells with intact BRCA function remain largely unaffected.
Prior to this study, many patients with a BRCA2 VUS could not be definitively identified as candidates for PARP inhibitor therapy. Now, with 91% of VUS in the DNA-binding domain classified, oncologists can more accurately identify patients who would benefit from these highly effective drugs, leading to more personalized and efficacious treatment plans. This could potentially extend survival and improve quality of life for a significant number of cancer patients.
4. Advancing Public Health and Economic Efficiency:
By reducing the ambiguity of VUS, the study contributes to public health by improving diagnostic accuracy and enabling more appropriate medical management. It can also lead to greater economic efficiency within the healthcare system by reducing the need for repeated tests, unnecessary surveillance, or inappropriate treatments based on inconclusive genetic data.
A Collaborative Endeavor and Future Horizons
The success of this comprehensive study is a testament to the power of multi-institutional and international collaboration. Key partners included Ambry Genetics Inc., Duke University, H. Lee Moffitt Cancer Center, the University of Pennsylvania, and several contributing studies from the CARRIERS consortium. This broad network of expertise and resources was instrumental in tackling such a complex and large-scale research project. The study received vital financial backing from prominent organizations, including the National Cancer Institute, the Mayo Clinic Breast Cancer SPORE (P50 CA116201), R35 Outstanding Investigator Programs, the Mayo Clinic Comprehensive Cancer Center, and the Breast Cancer Research Foundation, highlighting the recognized importance of this work.
Looking ahead, the researchers emphasize that this pioneering work lays a robust foundation for future studies. The immediate next steps involve characterizing and classifying all BRCA2 variants across its entire length, extending beyond the crucial DNA-binding domain. Furthermore, it highlights the need for similar comprehensive functional assessments for other key cancer predisposition genes, such as BRCA1, PALB2, CHEK2, and ATM, which also contribute significantly to hereditary cancer risk and frequently yield VUS results.
Crucially, future research will also need to focus on diverse populations. Genetic variants can have different frequencies and sometimes even different interpretations across various ethnic and racial groups. Ensuring that these classifications are universally applicable and equitable will be paramount in truly improving risk assessment for everyone, irrespective of their genetic background.
A New Era for Precision Oncology
The successful classification of 91% of BRCA2 VUS in its DNA-binding domain heralds a new era in precision oncology. It signifies a major step towards realizing the full potential of genetic information in preventing, detecting, and treating cancer. By transforming ambiguity into actionable insights, this study empowers patients and clinicians alike, offering clarity, hope, and the promise of truly personalized medicine in the fight against hereditary cancer. As genetic technologies continue to advance, this pioneering work serves as a blueprint for deciphering the complexities of the human genome, ultimately leading to better health outcomes for countless individuals worldwide.
